The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Designated as an emerging epidemic in 1997, heart failure (HF) remains a major clinical
and public health problem. This review focuses on the most recent studies identified by …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Systemic amyloidosis is a rare protein misfolding and deposition disorder leading to
progressive organ failure. There are over 15 types of systemic amyloidosis, each caused by …

Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly diagnosed owing to the
emergence of noninvasive imaging and improved awareness. Clinical penetrance of …

Importance Heart failure (HF) with preserved ejection fraction (HFpEF) is common, is
frequently associated with ventricular wall thickening, and has no effective therapy …

Often considered a rare disease, cardiac amyloidosis is increasingly recognized by
practicing clinicians. The increased rate of diagnosis is in part due the aging of the …

Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a life‐threatening condition with a
heterogeneous clinical presentation. The recent availability of treatment for ATTR‐CM has …

Systemic forms of amyloidosis affecting the heart are mostly light-chain (AL) and
transthyretin (ATTR) amyloidoses. The latter is caused by deposition of misfolded …